Argenica Therapeutics Addresses FDA’s Clinical Hold on Stroke Treatment

Argenica Therapeutics Ltd ( (AU:AGN) ) has shared an update.

Argenica Therapeutics has received feedback from the FDA regarding their clinical hold on the IND application for ARG-007, a treatment for acute ischaemic stroke. The FDA has requested additional safety data and in vitro studies to address data gaps, which Argenica plans to fulfill using existing and upcoming Phase 2 trial data. The company is working closely with the FDA to ensure these requirements are met to lift the clinical hold, which could significantly impact its operations and market position in stroke treatment.

The most recent analyst rating on (AU:AGN) stock is a Buy with a A$1.19 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.

More about Argenica Therapeutics Ltd

Argenica Therapeutics Limited is a biotechnology company focused on developing novel therapeutics aimed at reducing brain tissue death following a stroke. The company’s primary market focus is on acute ischaemic stroke treatment.

Average Trading Volume: 101,876

Technical Sentiment Signal: Buy

For a thorough assessment of AGN stock, go to TipRanks’ Stock Analysis page.